Varenicline modulates spatial working memory deficits in smokers with schizophrenia

Schizophrenia Research

Volumn 149, Issue 1-3, 2013, Pages 190-191

  Wing, Victoria C ^a   Wass, Caroline E ^a   Bacher, Ingrid ^a   Rabin, Rachel A ^a,b   George, Tony P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARENICLINE;

CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; HUMAN; LETTER; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; SPATIAL MEMORY; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; WORKING MEMORY;

ANALYSIS OF VARIANCE; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TESTS; NICOTINIC AGONISTS; PSYCHIATRIC STATUS RATING SCALES; QUINOXALINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING;

EID: 84881231540     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.06.032     Document Type: Letter

References (10)

1. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 2011, 2:CD006103.
2. Dolan S.L., Sacco K.A., Termine A., Seyal A.A., Dudas M.M., Vessicchio J.C., Wexler B.E., George T.P. Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr. Res. 2004, 70(2-3):263-275.
3. Hershey T., Craft S., Glauser T.A., Hale S. Short-term and long-term memory in early temporal lobe dysfunction. Neuropsychology 1998, 12(1):52-64.
4. Hong L.E., Thaker G.K., McMahon R.P., Summerfelt A., Rachbeisel J., Fuller R.L., Wonodi I., Buchanan R.W., Myers C., Heishman S.J., Yang J., Nye A. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 2011, 68(12):1195-1206.
5. Loughead J., Ray R., Wileyto E.P., Ruparel K., Sanborn P., Siegel S., Gur R.C., Lerman C. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol. Psychiatry 2010, 67(8):715-721.
6. Patterson F., Jepson C., Strasser A.A., Loughead J., Perkins K.A., Gur R.C., Frey J.M., Siegel S., Lerman C. Varenicline improves mood and cognition during smoking abstinence. Biol. Psychiatry 2009, 65(2):144-149.
7. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., Jatlow P.I., Wexler B.E., George T.P. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch. Gen. Psychiatry 2005, 62(6):649-659.
8. Shim J.C., Jung D.U., Jung S.S., Seo Y.S., Cho D.M., Lee J.H., Lee S.W., Kong B.G., Kang J.W., Oh M.K., Kim S.D., McMahon R.P., Kelly D.L. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012, 37(3):660-668.
9. Williams J.M., Anthenelli R.M., Morris C.D., Treadow J., Thompson J.R., Yunis C., George T.P. A double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 2012, 73(5):654-660.
10. Wing V.C., Wass C.E., Soh D.W., George T.P. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann. N. Y. Acad. Sci. 2012, 1248:89-106.